Medtronic’s Epilepsy Device Fails FDA Test (MDT, CYBX)

Medtronic’s (NYSE: MDT) new nerve stimulating implant has failed to meet its study goal.

The device is currently used to treat various movement disorders. Medtronic has sought FDA approval for the use of the implant for treating epilepsy. In a document, FDA has said that the implant failed to ensure reduction in the incidence of seizures.

One patient included in the study showed an increase in seizures after the use of the implant. Currently, epilepsy is usually treated by the use of medication, or through surgery in some cases.

Another medical device maker Cyberonics, Inc. (NASDAQ: CYBX) is also in the market with a nerve stimulator device.